This study looked at luteinizing hormone (LH) levels in women undergoing IVF treatment. LH is a natural hormone involved in the final maturation of eggs. The researchers wanted to see if the amount of LH measured on the day a final 'trigger' injection is given was linked to how well the IVF cycle worked. They examined data from 9,979 IVF cycles. Most of the cycles (8,786) were in women younger than 38 years old. Another 1,193 cycles were in women aged 38 or older. The study grouped the cycles based on the measured LH level on the trigger day. The goal was to see if being in a certain LH group was connected to different clinical outcomes, like pregnancy rates. The study did not report specific safety concerns or adverse events related to LH levels. The main reason to be careful is that this was a retrospective study. This means researchers looked back at past medical records. They found associations, but they cannot prove that the LH level itself caused any particular result. Other factors could explain the findings. Readers should know this research helps doctors understand patterns in IVF treatment. It suggests that LH levels might be one piece of the puzzle. However, it is not a guideline for changing treatment yet. More research is needed to understand if adjusting LH levels could improve outcomes.
Retrospective study examines LH concentration on trigger day in long-protocol IVF/ICSI cyclesStudy examines luteinizing hormone levels during IVF treatment in nearly 10,000 cycles
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This retrospective cohort study analyzed 9,979 IVF/ICSI cycles to investigate the impact of endogenous luteinizing hormone (LH) concentration on the day of hCG trigger during a long GnRH agonist protocol. The population was divided by age, with 8,786 cycles from women younger than 38 years and 1,193 cycles from women aged 38 years or older. The exposure was serum LH concentration, which was stratified into five groups for analysis. The study setting, comparator groups, primary and secondary outcomes, and duration of follow-up were not reported. The main results, including specific numerical data on clinical pregnancy, live birth, or other endpoints, were not provided in the available evidence. Safety and tolerability data, including adverse events and discontinuation rates, were also not reported. Key limitations inherent to the retrospective design, such as potential for confounding and selection bias, were not detailed. The funding sources and author conflicts of interest were not disclosed. The direct practice relevance of these findings remains unclear without reported outcome data, and the observational nature of the evidence precludes causal inference about optimal LH levels.